OCM
ANIK icon

Oakwood Capital Management’s Anika Therapeutics ANIK Stock Holding History

Oakwood Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,650
Closed -$406K – 72
2013
Q4 		$406K Buy
+10,650
New +$329K 0.14% 61

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oakwood Capital Management's ANIK Position: Q1 2014 in Review

Oakwood Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2014, closing a stake of 10,650 shares — an estimated $406K sold.

Oakwood Capital Management first reported a position in ANIK in Q4 2013 and held it in 1 quarter. The position peaked at $406K in Q4 2013. 153 funds tracked by Wall St. Rank hold ANIK as of Q1 2014.

  • Oakwood Capital Management reported no remaining Anika Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Oakwood Capital Management sold 10,650 Anika Therapeutics shares in Q1 2014, an estimated $406K.
  • Oakwood Capital Management first reported a position in Anika Therapeutics in Q4 2013 and held it in 1 quarter.
  • Oakwood Capital Management's Anika Therapeutics position peaked at $406K in Q4 2013.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2014.

Based on Oakwood Capital Management's 13F filing for Q1 2014, filed 17 Apr 2014.